Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.6K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

1.6K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

379
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
379
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.5K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictive and prognostic factors for immunotherapy response in head and neck squamous cell carcinoma: a narrative review.

Expert review of clinical pharmacology·2026
Same author

Predicting modelling for early diagnosis in early myeloproliferative neoplasms, not otherwise specified. Evidence from a machine learning study.

Frontiers in oncology·2026
Same author

Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group.

Expert opinion on pharmacotherapy·2026
Same author

Cross-Sectional Multicenter Biomonitoring Study on Genotoxicity and Oxidative DNA Damage in Oncology Healthcare Workers from Seven Italian Hospitals.

Journal of xenobiotics·2026
Same author

High-Throughput Molecular Characterization of the Microbiome in Breast Implant-Associated Anaplastic Large Cell Lymphoma and Peri-Implant Benign Seromas.

Cancers·2025
Same author

Correction: Abemaciclib early access - an Italian experience.

Frontiers in oncology·2025

Related Experiment Video

Updated: Dec 25, 2025

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
08:25

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

Published on: April 27, 2021

2.6K

Pharmacotherapy in Mast Cell Leukemia.

Mariarita Laforgia1, Concetta Calabrò1, Anna Scattone2

  • 1S.C. Farmacia e U.Ma.C.A, IRCCS Istituto Tumori Giovanni Paolo II , Bari, Italy.

Expert Opinion on Pharmacotherapy
|March 27, 2020
PubMed
Summary

Mast cell leukemia (MCL) is a rare and aggressive form of Systemic Mastocytosis (SM). Personalized therapy, considering KIT mutations, is crucial for effective MCL treatment due to limited options.

Keywords:
KIT activating mutationsadvanced systemic mastocytosismast cellsstem cell transplantationtyrosine kinase inhibitors

More Related Videos

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
09:07

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Published on: May 27, 2015

10.8K
Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays
11:31

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays

Published on: July 4, 2018

12.7K

Related Experiment Videos

Last Updated: Dec 25, 2025

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
08:25

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

Published on: April 27, 2021

2.6K
Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
09:07

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Published on: May 27, 2015

10.8K
Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays
11:31

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays

Published on: July 4, 2018

12.7K

Area of Science:

  • Hematology
  • Oncology
  • Rare Diseases

Background:

  • Mast cell leukemia (MCL) is a rare (<1%) and aggressive subtype of Systemic Mastocytosis (SM).
  • Limited standard therapies and clinical trials exist for MCL, often grouping it with other SM forms.
  • KIT dysregulation in MCL drives uncontrolled mast cell activation, resembling myeloid acute leukemia (AML).

Purpose of the Study:

  • To review current therapeutic approaches for Mast Cell Leukemia (MCL).
  • To provide expert opinion on the optimal treatment strategy for MCL.
  • To discuss the role of KIT mutations in MCL diagnosis and treatment.

Main Methods:

  • Review of symptomatic and targeted therapies for MCL.
  • Analysis of existing literature on Systemic Mastocytosis and Mast Cell Leukemia.
  • Expert opinion synthesis on personalized treatment strategies.

Main Results:

  • Current MCL treatment relies on symptomatic and targeted therapies, often extrapolated from broader SM protocols.
  • The aggressive nature of MCL necessitates a tailored therapeutic approach.
  • KIT mutations are central to MCL pathogenesis and potential therapeutic targets.

Conclusions:

  • Personalized therapy is paramount for achieving clinical success in Mast Cell Leukemia.
  • Incorporating KIT mutant forms as diagnostic criteria for advanced SM could benefit MCL patient management.
  • Further research into specific MCL therapies is warranted given the small patient population and complex mutational landscape.